



TRANSCENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.

October 10, 2011

The General Manager (Department of Corporate Services)
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

Dear Sir,

Sub: Transgene Biotek commences commercial production of DHA

We are pleased to announce the commencement of commercial manufacturing operations of DHA, an Omega-3 fatty acid used as a nutraceutical product in health foods and supplements. DHA is the first commercial manufacturing in the near future. Transgene has entered into an agreement to manufacture DHA at a third part facility where production will be ramped up over the coming months to

full commercial manufacturing operations of DHA, an Omega-3 fatty acid used as a nutraceutical product in health foods and supplements. DHA is the first commercial manufacturing in the near future. Transgene has entered into an agreement to manufacture DHA at a third part facility where production will be ramped up over the coming months to

DHA is one of a small group of Omega-3 fatty acids known as Essential Fatty Acids (EFAs) termed because humans cannot synthesize these molecules indirectly through diet. DHA (docosahexanoic acid) is a beneficial roles in heart and brain health, child and inflammation amongst other health functions. The awareness Omega-3 inclusion in diets - either as supplements or exponentially over the last decade. GOED (Global Organization the Omega-3 market at US\$ 18.6 billion (Rs.90,000 Cr) and

DHA is one of a small group of Omega-3 fatty acids known as Essential Fatty Acids (EFAs) termed because humans cannot synthesize these molecules indirectly through diet. DHA (docosahexanoic acid) is a beneficial roles in heart and brain health, child and inflammation amongst other health functions. The awareness Omega-3 inclusion in diets - either as supplements or exponentially over the last decade. GOED (Global Organization the Omega-3 market at US\$ 18.6 billion (Rs.90,000 Cr) and

Simultaneously, alongside the commercial production of DHA at third party facilities, Transgene is also undertaking an expansion of manufacturing capacity at the company's own Headquarters in Hyderabad. We expect to complete this expansion by the end of the current financial year.

Simultaneously, alongside the commercial production of DHA at third party facilities, Transgene is also undertaking an expansion of manufacturing capacity at the company's own Headquarters in Hyderabad. We expect to complete this expansion by the end of the current financial year.

In addition to the aforementioned API division, the company has an extensive and rapidly advancing pipeline of biotech products including drugs against various cancers, vaccines against Auto-immune disorders such as AIDS and MS, and a platform delivery protein and peptide based drugs by oral and transdermal route. With potential out-licensing of specific products within this biotech portfolio, coupled with the impending revenues from our API manufacturing, we estimate double-digit growth over the coming quarters as we harvest some of the seeds sown in recent years.

In addition to the aforementioned API division, the company has an extensive and rapidly advancing pipeline of biotech products including drugs against various cancers, vaccines against Auto-immune disorders such as AIDS and MS, and a platform delivery protein and peptide based drugs by oral and transdermal route. With potential out-licensing of specific products within this biotech portfolio, coupled with the impending revenues from our API manufacturing, we estimate double-digit growth over the coming quarters as we harvest some of the seeds sown in recent years.

Thanking you

Yours sincerely

For **TRANSCENE BIOTEK LIMITED**

S. S. MARTHI
DIRECTOR